Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE.
We investigated the effects of the amino acid and vitamin mixture SAAVE in inpatient, chemically-dependent subjects to evaluate the role of neurotransmitters in facilitating recovery and adjustment to a detoxified, sober state. SAAVE is formulated from amino acids that are precursors for neurotransmitters and neuromodulators thought to be involved in alcohol and drug seeking behavior. In a double-blind, placebo-controlled, randomized study of 62 alcoholics and polydrug abusers, SAAVE patients had a significantly reduced stress response as measured by the skin conductance level (SCL), and significantly improved Physical Scores and BESS Scores (behavioral, emotional, social and spiritual). After detoxification there was a six-fold decrease in AMA rates when comparing SAAVE vs. placebo groups. In this inpatient treatment experience SAAVE facilitated the rate of recovery and allowed patients to respond more fully and more quickly to the behavioral goals of the program, for example as measured by the BESS Score. The use of SAAVE to achieve enkephalinase inhibition and precursor amino acid loading in the acute inpatient treatment environment provides the practitioner with the potential ability to restore the neurochemical changes inherent to alcoholism and drug abuse. These findings increase our understanding of the clinically relevant neurobiological mechanisms which underlie compulsive disease.
Blum
K
K
University of Texas Health Sciences Center, Department of Pharmacology, San Antonio.
Trachtenberg
M C
MC
Elliott
C E
CE
Dingler
M L
ML
Sexton
R L
RL
Samuels
A I
AI
Cataldie
L
L
D000437:Alcoholism / Q000188:drug therapy* / Q000503:physiopathology; D000596:Amino Acids / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005526:Food, Formulated; D005712:Galvanic Skin Response / Q000187:drug effects; D006760:Hospitalization; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D010919:Placebos; D011355:Prodrugs / Q000494:pharmacology*; D013223:Statistics as Topic; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology
D000596:Amino Acids; D010919:Placebos; D011355:Prodrugs; D015260:Neprilysin